lenalidomide has been researched along with atrasentan in 1 studies
Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (atrasentan) | Trials (atrasentan) | Recent Studies (post-2010) (atrasentan) |
---|---|---|---|---|---|
3,532 | 725 | 2,850 | 358 | 41 | 108 |
Protein | Taxonomy | lenalidomide (IC50) | atrasentan (IC50) |
---|---|---|---|
Endothelin receptor type B | Homo sapiens (human) | 0.2221 | |
Endothelin-1 receptor | Homo sapiens (human) | 0.0001 | |
Endothelin-1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
Endothelin receptor type B | Sus scrofa (pig) | 0.315 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
1 review(s) available for lenalidomide and atrasentan
Article | Year |
---|---|
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |